The median preoptic nucleus (MnPN) 
INTRODUCTION
Adenosine (AD) is an endogenous sleep factor that has been shown to promote nonREM sleep (for review, see refs. 6, 7, 36 and 39) . Extracellular concentrations of adenosine in the basal forebrain increase during wakefulness and decrease during sleep (37) . Adenosine and adenosine agonists influence the activity of putative sleep-and wake-regulatory neurons (3, 40) . Sleep is increased by administration of adenosine, adenosine receptor agonists or drugs that increase extracellular adenosine levels in forebrain sites including the substantia innominata (37, 38) , magnocellular basal forebrain area (5) , subarachnoid space ventral to the rostral basal forebrain (SS-rBF) (15, (43) (44) (45) 46) and median and lateral preoptic areas (28, 29, 30, 55) . Two brain regions implicated in the regulation of sleep are the median preoptic nucleus (MnPN) and the ventrolateral preoptic area (VLPO) of the hypothalamus. A subset of MnPN neurons exhibit sleep-related discharge with low discharge during waking, increased activity with the onset of sleep, and the highest discharge during nonREM and REM sleep (51) . The number of MnPN neurons exhibiting c-Fos protein immunoreactivity (Fos-IR), a marker of neuronal activation, increases in proportion to the amount of preceding sleep and with increasing homeostatic sleep pressure (11) (12) (13) . VLPO neurons also exhibit increased discharge during nonREM and REM sleep, as well as sleep-associated Fos-IR (48, 52) . VLPO neurons appear critical for sleep induction and sleep maintenance, as excitotoxic VLPO lesions markedly decrease both nonREM and REM sleep (27) . Excitotoxic lesion of preoptic area (POA) that primarily involves the medial region also causes chronic sleep loss (18) .
There are four adenosine receptor subtypes, A 1 , A 2A , A 2B and A 3 , all of which are coupled to G proteins (42) . Inhibitory G protein-coupled adenosine A 1 (10, 43-45, 46, 56) . The largest increase in sleep occurs when CGS-21680 is administered to the SS-rBF (44) . CGS-21680-induced sleep is associated with an increase in Fos-IR in VLPO neurons (46) . A subset of VLPO neurons recorded in hypothalamic slice is excited by adenosine acting on the A 2A R (9) 
METHODS
Experiments were performed on male, Sprague-Dawley rats, weighing between 300-350g at the time of surgery. These rats were maintained on 12:12 h light-dark cycle (lights on at 06:00 h) and with food and water available ad libitum. All experiments were conducted in accordance with the National Research Council Guide for the Care and Use of Laboratory Animals and were approved by Institutional Animal Care and Use Committee, V.A. Greater Los Angeles Healthcare System.
Surgical Procedures
All surgical procedures were done under anesthesia (Ketamine + Xylazine: 80:10 mg/kg; i.p.) and aseptic conditions. Details of the surgical procedure were described previously (23) . In brief, rats were implanted with electroencephalogram (EEG) and dorsal neck electromyogram (EMG) electrodes for recording sleep-wake behavior. In addition rats were implanted with a microinjection guide cannula (23G stainless steel tube) in the lateral ventricle at coordinates, AP = -0.8 mm; L = 1.4 mm and H = 3.6 mm (34), or the SS-rBF, at co-ordinates, AP = +1.5 mm; L = 1.8 mm and H = 8.3 mm (44).
Following implantation a blocking stylet was inserted into the guide cannula to maintain patency until microinjection. Rats were permitted a 10-12 day post-surgical recovery period, after which they were connected to recording cables and placed in temperature controlled (23±2°C) and sound attenuated recording chambers for adaptation.
Experimental Protocols

Experiment-1: Effects of microinjection of CGS-21680 into the lateral ventricle on sleep and
Fos-IR
Three days before the experiments, the placement of ICV cannula was tested by ICV injection of angiotensin (200 ng in a volume of 5 µl). Only rats exhibiting a short-latency (<2 min) drinking response to angiotensin were used.
Control rats (n=7) received microinjection of vehicle containing 4% dimethyl sulfoxide (DMSO) in artificial cerebrospinal fluid (aCSF), of composition in mM, 145 NaCl, 2. All ICV injections were initiated at 14:00 (lights-on at 06:00). Drug or vehicle was injected during second half of the light phase because baseline sleep amounts are reduced compared to the early light phase, increasing the likelihood of detecting drug-induced increases in sleep. The rats were left undisturbed for 2 hours following ICV injection, while EEG and EMG were continuously recorded.
Experiment-2: Effects of microinjection of CGS-21680 into the SS-rBF on sleep and Fos-IR
In this experiment, rats received microinjection of vehicle (n=7, 4% DMSO in aCSF) or 8 nmol (n=7) CGS-21680 in a volume of 5μl over 10 minutes into the SS-rBF at 14:00. Rats were left undisturbed for 2 hours, while EEG and EMG were continuously recorded. 
Histology and Immunohistochemistry
At the end of all experiments, rats were given a lethal dose of pentobarbital (100 mg/kg, IP). Immediately after anesthetization, rats were injected with heparin (500U, i.p.), and perfused transcardially with 30-50 ml of 0.1 M phosphate buffered saline (PBS; pH 7.2) followed by 500 ml of 4% paraformaldehyde in PBS, containing 15% saturated picric acid solution (a final concentration of the picric acid was 0.2%). The brains were removed, post-fixed for 20 min and then equilibrated in 30% sucrose. Coronal sections encompassing the MnPN and VLPO were freeze-cut at 30µm thickness and immunostained for c-Fos and GAD. All sections were rinsed with TBS, mounted on gelatin-coated microscope slides, dehydrated in graded alcohols, cleared in xylene and cover slipped with DPX mounting medium.
Tissues from control and experimental groups of each experiment were processed together using the same batch of reagents. Omission of the primary antibodies (anti-Fos and anti-GAD) in control sections did not yield staining in processes, proximal dendrites or cell bodies.
Serial coronal sections were stained for Nissl (cresyl violet) for localization of microinjection sites. Sections stained for Fos-GAD were used for localization of microinjection sites for ICV experiments.
Data Analysis
Sleep-wake scoring: Bioelectric signals were amplified and band pass filtered at 0.3-100 Hz (EEG) or or10-300 Hz (EMG) (Model 78 D, Grass Instruments, Quincy, MA). Bioelectrical signals were digitized at a sampling rate of 128 Hz for EEG and 256 Hz for EMG using a 1401
Plus data acquisition interface and Spike2 software (Cambridge Electronic Design, Cambridge, UK) and stored on a PC for off-line analysis.
The predominant sleep-wake states for each 10-s epoch were visually determined by an experienced scorer, blind to experimental condition and group identity of the animals. Wake was defined as low-voltage, high frequency activity combined with elevated neck muscle tone. 
Cell counting and analyses:
A single person blind to the treatment conditions performed the counting and plotting of the immunoreactive neurons using the Neurolucida computer-aided plotting system (Micro Bright Field). Section outlines were drawn with 20x magnification, whereas the identification and counting of different neuronal types, i.e., single and dual labeled neurons were done manually under 400x magnification. Fos-IR was recognized by black stain localized to the nucleus, whereas brown-stained soma and dendrites identified GAD-containing neurons. Neurons having a black nucleus and a brown cytoplasm were identified as double labeled neurons.
Counts of Fos+, GAD+, and GAD+/Fos+ cells in MnPN and VLPO were performed using grids corresponding to the four areas of interest; rostral MnPN (rMnPN), caudal MnPN (cMnPN), core VLPO (cVLPO) and extended VLPO (eVLPO), as shown in Fig. 3 and described previously (21) . For both the rMnPN and the cMnPN, cell counts were made in three sections and averaged to yield a single value for each rat. For VLPO, cell counts were made bilaterally in three sections containing the largest part of the VLPO. Those six counts were then averaged to yield a single value for both the cVLPO and eVLPO (dorsal and medial combined boxes) for each rat.
Statistical analysis
The responses of various doses of CGS-21680 and ZM-24135 on single-labeled Fos+, GAD+, and double-labeled GAD+/Fos+ neurons in the MnPN and VLPO were compared with those obtained after vehicle treatments, using one-way ANOVA followed by Holm-Sidak test for pair-wise multiple comparisons. One-way ANOVA followed by Holm-Sidak tests were also used to determine the effects of CGS-21680 and ZM-241385 on sleep-wake parameters. The responses of an optimum dose of CGS-21680 into the SS-rBF on Fos-IR in GAD+ MnPN and VLPO neurons as well as sleep-wake parameters were compared with those observed after vehicle treatment using independent t-test.
RESULTS
Effects of ICV injection of CGS-21680
ICV administration of 24 nmol of CGS-21680 caused a significant decrease in % time awake and an increase in % time in nonREM sleep, compared to both the 8 nmol dose and vehicle ( Figure 1A ). The 24 nmol dose also increased % time in REM sleep compared to the vehicle. There were no significant differences in sleep-wake amounts between 8 nmol CGS- Figure 4 and Table   1 ). The number of Fos/GAD dual immunoreactive neurons and the %GAD+ neurons double-labeled did not differ significantly between vehicle and 8 nmol CGS-21680 treated animals in all of the four areas examined (Table 1 and Figure 4) .
Effects of SS-rBF injection of CGS-21680
Microinjection (Table 2) .
c-Fos expression in preoptic neurons in CGS-21680 treated sleep-deprived rats
To determine if treatment with CGS-21680 could activate MnPN and VLPO GABAergic neurons independent of increasing sleep, groups of drug-and vehicle-treated rats (n=7) were subjected to sleep deprivation for 2h post-injection, and then sacrificed without opportunity for recovery sleep. Drug and vehicle injections were made into the SS-rBF. Time (in min) spent awake and in nonREM sleep during the sleep deprivation period are shown in Figure 5A . There were no significant differences between CGS-21680-and vehicle-treated rats. REM sleep was completely suppressed in both groups during sleep deprivation (data not shown).
In spite of the comparable reductions in sleep achieved in the two groups, the percentage of GAD-IR neurons dual immunolabeled for Fos-IR was significantly elevated in all MnPN and VLPO subregions examined in CGS-2160-treated versus vehicle-treated rats (Figure 4) . The number of GAD/Fos dual IR cells was also elevated in the MnPN and VLPO of animals treated with drug ( Table 2) . ICV infusion of ZM-241385 resulted in significant decreases in the %Fos+/GAD+ neurons in both the rostral and caudal portions of the MnPN (Figure 7 ). Significant decreases in %GAD+ neurons double-labeled were also observed in the core and extended VLPO in response to drug (Figure 7) . Dual Fos/GAD-IR cell counts were also reduced in these preoptic nuclei in response to drug (Table 3 ). There were no significant differences in single GAD-IR or single Fos-IR cell counts between drug-and vehicle-treated animals in any of the preoptic nuclei examined (Table 3) .
Effects of ICV infusion of
DISCUSSION
The ICV administration of an adenosine A 2A R agonist, CGS-21680, increased both nonREM and REM sleep amounts, increased delta power within nonREM sleep, and increased 
